IDEAYA Reports Q3 2026 Results, $1.15 Billion in Cash and Darovasertib NDA Submission

What happened

IDEAYA reported a third-quarter 2026 net loss of $125.7 million and collaboration revenue of $10.2 million. It ended September with $1.15 billion in cash, cash equivalents and marketable securities, kept its cash runway guidance into 2030, and completed an NDA submission for darovasertib in metastatic uveal melanoma.

Confirmed

Global impact / market context

The large cash balance of $1.15 billion, which the company says lasts into 2030, reduces the near-term need to raise outside money while the drug application is reviewed. That matters because research and development spending rose to $121.6 million, so a steady cash base protects the launch plan.

Analyst inference

The wider net loss reflects higher research and development costs, which means the company is spending more to push darovasertib toward approval. Investors will weigh that rising cost against the filed FDA application and the stated cash runway, since the review outcome now drives the company's outlook.

Analyst inference

What to watch

1. Watch whether the FDA accepts the darovasertib NDA submission under the Real-Time Oncology Review program, which means a faster review path, and what timing the agency gives. Confirmed
2. Track quarterly research and development expenses, since they rose from $108.7 million to $121.6 million, as faster spending would shorten the stated cash runway into 2030. Analyst inference
3. Watch how the company funds any commercial launch of darovasertib, because launch costs could add to the current net loss of $125.7 million per quarter. Analyst inference

Evidence

• Original source link unavailable